drugset
drugset / Trial / NCT06005974

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

NCT06005974 ↗

Phase 2 Terminated 18 enrolled Recursion Pharmaceuticals Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.

Timeline

Start
2024-01-15
Primary completion
2025-02-24
Completion
2025-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-733 Small molecule 12 mg Oral

Indications

neoplasm